XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Public ClinicalTrials.gov record NCT05005728. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Multiple-Dose, Multiple-Arm, Parallel Assignment Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapies in Selected Subjects With Metastatic Castration-Resistant Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior therapy.
Study identification
- NCT ID
- NCT05005728
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 72 participants
Conditions and interventions
Interventions
- vudalimab + carboplatin + cabazitaxel Combination Product
- vudalimab + olaparib Combination Product
- vudalimab monotherapy Biological
- vudalimab + docetaxel Combination Product
- vudalimab + cabazitaxel or docetaxel Combination Product
Combination Product · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 22, 2021 (Actual)
- Primary completion
- Jun 10, 2025 (Actual)
- Completion
- Jun 10, 2025 (Actual)
- Last update posted
- May 5, 2026
2021 – 2025
United States locations
- U.S. sites
- 26
- U.S. states
- 20
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Oncology and Hematology | Anchorage | Alaska | 99508 | — |
| Palo Verde Hematology Oncology | Glendale | Arizona | 85304 | — |
| Mayo Clinic Hospital | Phoenix | Arizona | 85054 | — |
| City of Hope | Duarte | California | 91010 | — |
| VA Greater Los Angeles | Los Angeles | California | 90064 | — |
| University of California, San Diego | San Diego | California | 92093 | — |
| Rocky Mountain Cancer Centers | Lone Tree | Colorado | 80124 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| The University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| University of Iowa Hospitals & Clinics | Iowa City | Iowa | 52242 | — |
| University of Kansas Clinical Research Center | Fairway | Kansas | 66205 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| GU Research Network/Urology Cancer Center | Omaha | Nebraska | 68130 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89148 | — |
| XCancer New Mexico Oncology Hematology Consultants, Ltd. | Albuquerque | New Mexico | 87109 | — |
| Columbia University | New York | New York | 10032 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Northwest Cancer Specialists | Tigard | Oregon | 97223 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Carolina Urologic Research Center | Myrtle Beach | South Carolina | 29572 | — |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | — |
| Texas Oncology-Central South | Weslaco | Texas | 78596 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| University of Washington/Seattle Cancer Care/Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05005728, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 5, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05005728 live on ClinicalTrials.gov.